Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Short-term Investments (2016 - 2025)

Arcadia Biosciences filings provide 10 years of Short-term Investments readings, the most recent being $4.3 million for Q4 2025.

  • On a quarterly basis, Short-term Investments changed N/A to $4.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.3 million, a N/A change, with the full-year FY2025 number at $4.3 million, changed N/A from a year prior.
  • Short-term Investments hit $4.3 million in Q4 2025 for Arcadia Biosciences, down from $4.8 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $19.1 million in Q1 2021 to a low of $2.6 million in Q2 2024.
  • Median Short-term Investments over the past 4 years was $4.9 million (2023), compared with a mean of $5.7 million.
  • Biggest five-year swings in Short-term Investments: surged 526.86% in 2021 and later crashed 49.02% in 2024.
  • Arcadia Biosciences' Short-term Investments stood at $19.1 million in 2021, then crashed by 73.16% to $5.1 million in 2023, then plummeted by 49.26% to $2.6 million in 2024, then soared by 65.54% to $4.3 million in 2025.
  • The last three reported values for Short-term Investments were $4.3 million (Q4 2025), $4.8 million (Q3 2025), and $3.1 million (Q2 2025) per Business Quant data.